Oncolytics Biotech announced the publication of the first study that shows that the reovirus directly activates human dendritic cells, and that reovirus-activated dendritic cells stimulate innate killing by natural killer cells and T cells. This suggests a new potential role for T cells in oncolytic virus-induced local tumor cell death.
Read the press release here or below.
Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that Prof. Alan Melcher and his research group at St. James’s University Hospital in Leeds, U.K. published the results of their work with reovirus in the May 1, 2008 online issue of The Journal of Immunology. The paper is entitled “Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity.”
The researchers studied the ability of reovirus to activate human dendritic cells (DC), key regulators of both innate and adaptive immune responses. The data demonstrated that reovirus directly activates human DC, which in turn stimulate innate killing of cancer cells by natural killer (NK) and T cells, suggesting a novel potential role for T cells in oncolytic virus-induced local tumor cell death. Combined with the virus’s ability to directly kill cancer cells, the researchers concluded that reovirus recognition by DC may enhance the efficacy of reovirus as a therapeutic agent.
“This research provides additional insight into how reovirus interacts with the immune system, and expands our understanding of its multiple roles in the killing of cancer cells,” said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.
To read the journal abstract click here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment